On the heels of solid tumor data and with competitors surging, Poseida scraps autologous CAR-T in favor of allo
Poseida CEO Eric Ostertag was not shy about the prospects he sees for autologous CAR-T therapies in the age of off-the-shelf alternatives: They are “going the way of the dinosaur.”
His company is officially starting that pivot.
In its quarterly update, San Diego-based Poseida announced that it’s winding down the P-BCMA-101 autologous program, one of its former leads, as part of a “planned strategic shift to allogeneic BCMA” — namely P-BCMA-ALLO1.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,200+ biopharma pros reading Endpoints daily — and it's free.